-- ネオボルタ（NEOV）は、ジョージア州ペンダーグラスにある米国バッテリーエネルギー貯蔵システム製造合弁会社、ネオボルタ・パワーへの出資比率を60%から80%に引き上げた。 ネオボルタは火曜日の声明で、残りの20%は引き続きポティスエッジの米国子会社であるCCCが保有すると発表した。 ネオボルタによると、今回の取引には新たな資金支出は必要ない。 ネオボルタは合弁会社の取締役会および経営権を完全に掌握しており、今回の組織再編は米国の製造業優遇措置制度に適合するように設計されている。 また、ネオボルタはポティスエッジと販売、マーケティング、事業開発に関する契約を締結し、その対価として普通株式120万株を発行することに合意した。
Price: $3.10, Change: $-0.02, Percent Change: -0.64%
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.